Is total body irradiation a necessary component of preparative therapy for autologous transplantation in non-Hodgkin's lymphoma

Leukemia & Lymphoma
R S SteinS N Wolff

Abstract

Between September 1986 and June 1998, 157 patients with low grade, intermediate grade, or high grade lymphoma underwent autologous transplantation at a single institution. Two preparative regimens were used: cyclophosphamide, etoposide, total body irradiation (CY-VP-TBI) (N=110) and cyclophosphamide, BCNU, etoposide (CBV) (N=47). The two groups were not significantly different with respect to source of stem cells, gender, stage at presentation, incidence of prior bone marrow involvement, sensitivity to salvage therapy, or histologic grade of lymphoma. The CBV group was significantly older, 49% of patients over age 50, as compared to 26% of patients over age 50 for the CY-VP-TBI group. Response rates and the incidence of fatal toxicity were similar for the two groups. Five year actuarial survival was 31% +/- 9% for CBV and 38% +/- 5% for CY-VP-TBI, p =.85. In a multivariate analysis, in which preparative regimen, age, histologic grade of lymphoma, and sensitivity to salvage therapy were the independent variables, TBI was not significantly associated with survival, and the direction of the trend was for TBI to be less effective than CBV. TBI does not appear to be an essential component of preparative therapy for autologous transp...Continue Reading

References

Oct 1, 1994·Journal of Molecular Endocrinology·R HosseiniK Dudley
Oct 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A S Freedman, L M Nadler
Jun 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W S VelasquezF Cabanillas
Jun 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A Z RohatinerJ Matthews
Feb 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P J BiermanJ O Armitage

❮ Previous
Next ❯

Citations

Jun 12, 2003·Current Opinion in Hematology·Vassiliki Rizouli, John G Gribben
Oct 8, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Steven N WolffF Anthony Greco
May 20, 2009·Psychonomic Bulletin & Review·Gregory V Jones, Maryanne Martin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.